Progabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. In clinical trials, progabide has been investigated for Parkinson's disease, schizophrenia, clinical depression and anxiety disorder; its therapeutic effectiveness in these conditions is not fully elucidated.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Progabide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Progabide. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Progabide. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Progabide. |
| Hydrocodone | Progabide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Progabide. |
| Magnesium sulfate | The therapeutic efficacy of Progabide can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Progabide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Progabide may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Progabide. |
| Mirtazapine | Progabide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Progabide. |
| Orphenadrine | Progabide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Progabide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Progabide. |
| Pramipexole | Progabide may increase the sedative activities of Pramipexole. |
| Ropinirole | Progabide may increase the sedative activities of Ropinirole. |
| Rotigotine | Progabide may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Progabide. |
| Sodium oxybate | Progabide may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Progabide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Progabide. |
| Thalidomide | Progabide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Progabide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Mefloquine | The therapeutic efficacy of Progabide can be decreased when used in combination with Mefloquine. |
| Mianserin | The therapeutic efficacy of Progabide can be decreased when used in combination with Mianserin. |
| Orlistat | Orlistat can cause a decrease in the absorption of Progabide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Topotecan | Progabide may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Methylphenidate | The risk or severity of adverse effects can be increased when Methylphenidate is combined with Progabide. |
| Dexmethylphenidate | The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Progabide. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Progabide. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Progabide is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Progabide is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Progabide is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Progabide is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Progabide is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Progabide is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Progabide is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Progabide is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Progabide is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Progabide is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Progabide is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Progabide is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Progabide is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Progabide is combined with (S)-Warfarin. |
| Tetracosactide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Progabide. |
| Ethanol | Progabide may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Progabide may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Progabide. |
| Zimelidine | The risk or severity of adverse effects can be increased when Progabide is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Progabide is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Progabide is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Progabide is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Progabide is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Progabide is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Progabide is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Progabide is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Progabide is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Progabide is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Progabide is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Progabide is combined with Escitalopram. |
| Milnacipran | The risk or severity of adverse effects can be increased when Progabide is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Progabide is combined with Desvenlafaxine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Progabide is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when Progabide is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Progabide is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Progabide is combined with Alaproclate. |
| Bifeprunox | The therapeutic efficacy of Progabide can be decreased when used in combination with Bifeprunox. |
| Lumateperone | The therapeutic efficacy of Progabide can be decreased when used in combination with Lumateperone. |
| Brexpiprazole | The therapeutic efficacy of Progabide can be decreased when used in combination with Brexpiprazole. |
| Blonanserin | The therapeutic efficacy of Progabide can be decreased when used in combination with Blonanserin. |
| Periciazine | The therapeutic efficacy of Progabide can be decreased when used in combination with Periciazine. |
| Thioproperazine | The therapeutic efficacy of Progabide can be decreased when used in combination with Thioproperazine. |
| Loxapine | The therapeutic efficacy of Progabide can be decreased when used in combination with Loxapine. |
| Promazine | The therapeutic efficacy of Progabide can be decreased when used in combination with Promazine. |
| Prochlorperazine | The therapeutic efficacy of Progabide can be decreased when used in combination with Prochlorperazine. |
| Chlorpromazine | The therapeutic efficacy of Progabide can be decreased when used in combination with Chlorpromazine. |
| Fluphenazine | The therapeutic efficacy of Progabide can be decreased when used in combination with Fluphenazine. |
| Thioridazine | The therapeutic efficacy of Progabide can be decreased when used in combination with Thioridazine. |
| Trifluoperazine | The therapeutic efficacy of Progabide can be decreased when used in combination with Trifluoperazine. |
| Perphenazine | The therapeutic efficacy of Progabide can be decreased when used in combination with Perphenazine. |
| Mesoridazine | The therapeutic efficacy of Progabide can be decreased when used in combination with Mesoridazine. |
| Pimozide | The therapeutic efficacy of Progabide can be decreased when used in combination with Pimozide. |
| Chlorprothixene | The therapeutic efficacy of Progabide can be decreased when used in combination with Chlorprothixene. |
| Molindone | The therapeutic efficacy of Progabide can be decreased when used in combination with Molindone. |
| Thiothixene | The therapeutic efficacy of Progabide can be decreased when used in combination with Thiothixene. |
| Zuclopenthixol | The therapeutic efficacy of Progabide can be decreased when used in combination with Zuclopenthixol. |
| Azaperone | The therapeutic efficacy of Progabide can be decreased when used in combination with Azaperone. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Progabide. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Progabide. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Progabide is combined with Cocaine. |
| Quinidine | The therapeutic efficacy of Progabide can be decreased when used in combination with Quinidine. |
| Zopiclone | The risk or severity of adverse effects can be increased when Progabide is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Progabide. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Progabide. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Progabide. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Progabide. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Progabide. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Progabide. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Progabide. |